ArticleScientific reports2023
Complex implementation factors demonstrated when evaluating cost-effectiveness and monitoring racial disparities associated with [
Article in Scientific reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Utilization of prostate-specific membrane antigen positron emission tomography in Australia following government subsidization: Trends in primary staging and biochemical recurrence.Prostate international · 2026Article
- Low-count whole-body PET denoising with deep learning in a multicenter, multi-tracer and externally validated study.European journal of nuclear medicine and molecular imaging · 2026Article
- Cost-Effectiveness and Evidence Gaps Surrounding PSMA-PET for Recurrent Prostate Cancer Evaluation.JAMA network open · 2025Article
- Geographic variability in contemporary utilization of PET imaging for prostate cancer: a medicare claims cohort study.Cancer imaging : the official publication of the International Cancer Imaging Society · 2025Article
- Reasons for Discordance betweenCancers · 2024Article
- Alternate CMS Payment Structure for Outpatient Services: A Road to Improving Access to Molecular Imaging in Oncologic Care.Radiology. Imaging cancer · 2023Article
- PSMA PET/CT cost-effectiveness analysis in the USA: a response to a published commentary.European journal of nuclear medicine and molecular imaging · 2023Article
- Up-to-Date Imaging and Diagnostic Techniques for Prostate Cancer: A Literature Review.Diagnostics (Basel, Switzerland) · 2023Review
- Cost-effectiveness of PSMA-PET imaging technology in diagnosing and staging of prostate cancer: a systematic review.Therapeutic advances in urologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Prostate cancer (PC) staging with conventional imaging often includes multiparametric magnetic resonance (MR) of the prostate, computed tomography (CT) of the chest, abdomen, and pelvis, and whole-body bone scintigraphy. The recent development of highly sensitive and specific prostate specific membrane antigen (PSMA) positron emission tomography (PET) has suggested that prior imaging techniques may be insufficiently sensitive or specific, particularly when evaluating small pathologic lesions. As PSMA PET/CT is considered to be superior for multiple clinical indications, it is being deployed as the new multidisciplinary standard-of-care. Given this, we performed a cost-effectiveness analysis of [
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.